Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most safety-related statements (serious infections, hospitalization/death, TB, hepatitis B reactivation, malignancy/lymphoma) are consistent with the provided excerpts, but multiple claims are not supported by the supplied label text (e.g., specific immune/blood/neurologic/demyelination and live vaccine guidance), and several statements are not directly grounded in the excerpts (e.g., TB can develop/reactivate in untreated/latent populations; specific hepatitis B reactivation labeling; post-stopping risk decrease).
Category Scores
Accurate Statements
Humira has warnings about serious infections.
5.1 Serious Infections: "Patients treated with HUMIRA are at increased risk for developing serious infections... may lead to hospitalization or death."
Serious infections associated with Humira may require hospitalization.
5.1 Serious Infections: "...may lead to hospitalization or death."
Serious infections associated with Humira can be fatal.
5.1 Serious Infections: "...may lead to hospitalization or death."; 6.1: "Some cases of serious opportunistic infections and TB have been fatal."
Humira has a warning about tuberculosis (TB).
5.1 Serious Infections: "...opportunistic ... pathogens including ... tuberculosis have been reported..."
Humira has warnings about lymphoma and other malignancies.
5.2 Malignancies: "Malignancies... have been reported..."; includes lymphoma references.
Humira has warnings about blood problems.
Humira is used with caution in people who have significant heart failure.
Unsupported Statements
Humira dampens parts of the immune system.
Not supported by the provided label excerpts.
Humira can cause active TB to develop.
The excerpts state TB has been reported with TNF blockers, but the specific causal phrasing "can cause active TB to develop" is not explicitly supported in the provided text.
Humira can reactivate old TB.
Reactivation language is not explicitly present in the supplied excerpts.
Humira has warnings about hepatitis B reactivation.
Hepatitis B reactivation is not included in the provided label excerpts.
Hepatitis B reactivation can occur in people who carry hepatitis B virus.
Not supported by the provided excerpts.
Humira may be associated with neurologic events.
Neurologic/demyelinating events are not mentioned in the provided excerpts.
Neurologic events associated with Humira include demyelinating disorders.
Not supported by the provided excerpts.
Humira has warnings about blood problems.
Blood disorders are not mentioned in the provided excerpts.
Humira has warnings about rare blood and immune-related problems.
Not supported by the provided excerpts.
Humira has warnings about immune reactions.
No immune reaction/hypersensitivity details are present in the provided excerpts.
Serious hypersensitivity reactions are possible with Humira.
No hypersensitivity statements appear in the provided excerpts.
Injection-site reactions are common with many biologics.
Injection-site reactions are not addressed in the provided excerpts.
Patients should contact a clinician promptly for signs of infection such as fever, persistent cough, unexplained weight loss, short of breath, or unusual fatigue.
Symptom list for when to contact a clinician is not provided in the excerpts.
Patients should contact a clinician promptly for symptoms that could suggest hepatitis B flare (for example, jaundice).
Hepatitis B flare/jaundice guidance is not supported by the provided excerpts.
Patients should contact a clinician promptly for symptoms that could suggest blood disorders such as easy bruising or unusual bleeding.
Blood disorder symptom guidance is not supported by the provided excerpts.
Humira can increase the risk of lymphoma and other malignancies.
The label excerpts discuss risk/occurrence, but the specific phrasing "can increase" is not directly stated in the provided text; additionally, the excerpt emphasizes "have been reported" rather than mechanistic risk increase language.
Anti-TNF medicines share safety themes with other TNF inhibitors.
Not addressed in the provided excerpts.
Switching within the TNF inhibitor class may change which specific adverse effects occur in a patient.
Not addressed in the provided excerpts.
The overall warning framework for TNF inhibitors remains relevant: serious infection risk, TB, hepatitis B reactivation, and malignancy signals.
Hepatitis B reactivation is not in the provided excerpts; class-wide generalization is not supported by provided text.
Humira risk tends to be higher for people with recurrent or chronic infections.
Risk stratification for recurrent/chronic infections is not explicitly stated in the provided excerpts.
Humira risk tends to be higher for people with untreated or latent TB or hepatitis B.
The provided excerpts indicate risk factors for infection include age/comorbidity/concomitant immunosuppressants, but "untreated or latent TB or hepatitis B" is not explicitly stated in the excerpts.
Humira risk tends to be higher for older adults or people with significant comorbidities.
The excerpts do state patients 65+ and those with co-morbidity may be at greater risk, so this is partially aligned; however, the statement is generic and not tied to the excerpt’s exact wording. Still, it is largely consistent with 5.1.
Humira risk tends to be higher for people with risk factors that already increase malignancy risk, such as certain prior immune-modulating therapies.
Not supported by the provided excerpts.
TB testing and hepatitis B screening are recommended before starting Humira.
The provided excerpts do not include screening recommendations.
Humira treatment involves monitoring for infections and cancer symptoms during therapy.
General monitoring is not explicitly described in the provided excerpts.
Live vaccines are typically avoided during treatment with Humira, depending on the situation.
Live vaccine guidance is not included in the provided excerpts.
Humira risk generally decreases after stopping because it is cleared over time.
No post-discontinuation clearance/risk decrease statements are present in the provided excerpts.
Immune effects and infection risk can persist while the body returns to baseline after stopping Humira.
Not supported by the provided excerpts.
Clinicians still assess risks around recent exposure after stopping Humira, especially for TB symptoms or hepatitis B reactivation.
Hepatitis B reactivation is not in the provided excerpts; and post-stopping assessment timing is not addressed.
Monitoring may continue for a period after discontinuation depending on the condition being treated and baseline risk.
Not supported by the provided excerpts.
Contradictions
Important Omissions
No specific contraindications, boxed warning text, drug interactions, detailed dosage/administration instructions, or concrete monitoring instructions (beyond the provided symptom-contact suggestions) were evaluated against the label excerpts.
Importance:
Moderate
The provided label excerpt includes specific language to not initiate HUMIRA in patients with active infection and to discontinue upon serious infection/sepsis; the AI response did not explicitly include these operational directives.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several safety themes align with the excerpts (serious infections with hospitalization/death; TB and malignancy/lymphoma). However, multiple critical safety details either are unsupported by the supplied excerpts or omit specific label directives (e.g., not initiating with active infection; discontinuing with serious infection/sepsis). This reduces label-alignment reliability for safe use interpretation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Several claims (notably hepatitis B reactivation, neurologic/demyelination, blood disorders/hypersensitivity, live vaccine avoidance, and post-discontinuation risk) are not supported by the provided FDA label excerpts.
Suggested Improvement
Limit statements to what is explicitly present in the provided label excerpts or supply the additional label sections covering hepatitis B reactivation, neurologic events, hematologic/blood disorders, hypersensitivity, vaccines, screening, and post-discontinuation monitoring; also include the excerpted operational instructions (do not initiate in active infection; discontinue if serious infection or sepsis; prompt diagnostic workup and antimicrobial therapy).